AFPep: an anti-breast cancer peptide that is orally active
- 15 March 2006
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 98 (2) , 133-141
- https://doi.org/10.1007/s10549-005-9140-5
Abstract
We have synthesized a cyclic nonapeptide (AFPep) that is effective, after being administered by parenteral routes, for the treatment or the prevention of breast cancer. To test the hypothesis that AFPep remains safe and efficacious after oral administration, three different whole-animal bioassays were utilized, and the mechanism by which AFPep functions was investigated. Using a human breast cancer xenograft model in mice for therapeutic activity, a carcinogen-induced breast cancer model in rats for prevention efficacy, and a mouse uterus growth inhibition model of anti-estrogenic activity, AFPep was administered by oral gavage (p.o.) and its effects compared to those following intraperitoneal (i.p.) and subcutaneous (s.c.) administration. Toxicity studies evaluated body weights and organ weights in mice and rats receiving AFPep. Preliminary mechanistic studies were carried out in T47D human breast cancer cells growing in culture and evaluated the effect of AFPep on estrogen-stimulated cell growth, phosphorylation of the estrogen receptor (ER), and on level of ER-related kinases. Orally administered AFPep stopped the growth of human tumor xenografts in mice, decreased the incidence and multiplicity of breast cancers in carcinogen-exposed rats, and inhibited the estrogen-stimulated growth of mouse uteri. In each of these systems, orally administered AFPep produced an effect similar to that obtained for AFPep administered by either i.p or s.c. routes. In rodents, no evidence of toxicity was seen for the peptide, even at very high doses. In culture, AFPep inhibited the estrogen-stimulated growth, but not the basal growth, of T47D cells, and it inhibited the estrogen-stimulated phosphorylation of Serine 118 in the ER of these cells, which was not explainable by early changes in ER-related kinases. Chronic oral administration of AFPep appears to be safe and effective for the treatment or prevention of breast cancer in animal models.Keywords
This publication has 14 references indexed in Scilit:
- Prevention of N-Methyl-N-Nitrosourea–Induced Breast Cancer by α-Fetoprotein (AFP)–Derived Peptide, a Peptide Derived from the Active Site of AFPClinical Cancer Research, 2005
- Thyroid Hormone Causes Mitogen-Activated Protein Kinase-Dependent Phosphorylation of the Nuclear Estrogen ReceptorEndocrinology, 2004
- Synthetic peptide derived from α‐fetoprotein inhibits growth of human breast cancer: investigation of the pharmacophore and synthesis optimizationChemical Biology & Drug Design, 2004
- A peptide derived from α-fetoprotein prevents the growth of estrogen-dependent human breast cancers sensitive and resistant to tamoxifenProceedings of the National Academy of Sciences, 2002
- Development of a synthetic cyclized peptide derived from α‐fetoprotein that prevents the growth of human breast cancerChemical Biology & Drug Design, 2001
- Orally Active Peptidomimetic RGD Analogs that are Glycoprotein IIb/IIIa AntagonistsCurrent Medicinal Chemistry, 2000
- Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategiesAdvanced Drug Delivery Reviews, 1997
- Similarity between natural and recombinant human alpha-fetoprotein as inhibitors of estrogen-dependent breast cancer growth.Breast Cancer Research and Treatment, 1997
- Automated Allyl Cleavage for Continuous-Flow Synthesis of Cyclic and Branched PeptidesAnalytical Biochemistry, 1993
- Alpha-Fetoprotein: A ReviewCRC Critical Reviews in Clinical Laboratory Sciences, 1981